Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, March 11, 2014 LONDON, March 11, 2014 /PRNewswire/ -- On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at: http://investor-edge.com/register Shares in Rexahn Pharmaceuticals Inc. closed at $1.25 on Monday, which is 5.68% lower than the previous day's closing price of $1.32. A total of 8.48 million shares were traded, which is below the three months average volumes of 11.22 million. The company's shares oscillated between $1.22 and $1.32 during the trading session. Rexahn Pharmaceuticals Inc.'s shares have rallied 11.16% in the last one month, 215.19% in the previous three months and 144.12% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. The company's 50-day moving average of $1.03 is above the 200-day moving average of $0.60. Furthermore, the stock is trading at the Relative Strength Index (RSI) of 58.19. Sign up and read the free notes on RNN at: http://www.Investor-Edge.com/03112014/RNN/report.pdf Amgen Inc.'s stock witnessed trading of 3.79 million shares, as compared with a three month average volume of 3.29 million shares. The stock ended the day at $125.40, up 2.57% and at an intraday trading range of $122.25 and $126.10 during the session. The stock traded at a PE ratio of 17.15. Amgen Inc.'s shares have gained 4.24% in the last one month, 9.90% in the previous three months and 9.92% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Amgen Inc.'s 50-day moving average of $119.82 is above the 200-day moving average of $111.66. Additionally, shares of the company are trading at the Relative Strength Index (RSI) of 49.83. The complimentary notes on AMGN can be downloaded as in PDF format at: http://www.Investor-Edge.com/03112014/AMGN/report.pdf On Monday, shares in Galena Biopharma Inc. surged 4.76% finishing the session at $3.52. The stock recorded trading volume of 5.13 million shares as compared to a three months average volume of 8.99 million shares. The company's shares fluctuated between $3.38 and $3.65 during the session and traded at a PE ratio of 29.33. Galena Biopharma Inc.'s shares have gone down by 9.28% in the previous three trading sessions, 34.69% in the last one month, and 29.03% on YTD basis. The stock is trading above its 200-day moving average. Galena Biopharma Inc.'s 50-day moving average of $4.92 is above the 200-day moving average of $3.07. Moreover, shares of the company are trading at the Relative Strength Index (RSI) of 35.08. Register for free on Investor-Edge and access the latest research on GALE at: http://www.Investor-Edge.com/03112014/GALE/report.pdf Shares in MannKind Corp. recoded a trading volume of 5.65 million shares, as compared with a three month average volume of 7.16 million shares. The stock ended Monday's session flat at the previous day's closing price of $5.71 after vacillating between $5.60 and $5.85. Shares in MannKind Corp. have advanced 0.35% in the last one month, 15.59% in the previous three months and 9.81% on YTD basis. The company's shares are trading above its 50-day moving average. MannKind Corp.'s 200-day moving average of $5.98 is above the 50-day moving average of $5.70. Furthermore, the stock is trading at the Relative Strength Index (RSI) of 45.73. The complete research on MNKD is available for free at: http://www.Investor-Edge.com/03112014/MNKD/report.pdf About Investor-Edge.com At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities. ============= EDITOR NOTES: ============= oThis is not company news. We are an independent source and our views do not reflect the companies mentioned. oInformation in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. oThis information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. oIf you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] Investor-edge.com. oFor any urgent concerns or inquiries, please contact us at compliance [at] Investor-edge.com. oAre you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] Investor-edge.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Investor-Edge Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
Press spacebar to pause and continue. Press esc to stop.